Search

Your search keyword '"Proietti E"' showing total 379 results
Start Over Author "Proietti E"
379 results on '"Proietti E"'

6. Premessa

Author

Acconcia, V., Boi, V., Milletti, M., and Proietti, E.

Published
2023

12. P555 Ustekinumab tissue and serum levels in patients with Crohn’s disease are closely correlated though not consistently associated with objective response after induction

Author

Proietti, E, primary, Bayoumy, A, additional, Pauwels, R, additional, van der Woude, J, additional, Doukas, M, additional, Oudijk, L, additional, Peppelenbosch, M, additional, Grohmann, U, additional, Crombag, R, additional, de Vries, A, additional, and Fuhler, G, additional

Published
2022
Full Text
View/download PDF

16. Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

Author

Lonardi, S., Nasti, G., Fagnani, D., Gemma, D., Ciuffreda, L., Granetto, C., Lucchesi, S., Ballestrero, A., Biglietto, M., Proserpio, I., Bergamo, F., Proietti, E., Tonini, G., and Soto Parra, H

Subjects
Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Genotype, Bevacizumab, Colorectal cancer, First line, Angiogenesis Inhibitors, Metastatic colorectal cancer, bevacizumab, clinical practice, progression-free survival, therapy interruption, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, Medicine, Progression-free survival, Neoplasm Metastasis, Aged, business.industry, General Medicine, Middle Aged, medicine.disease, Discontinuation, 030104 developmental biology, Italy, 030220 oncology & carcinogenesis, Mutation, Mutation (genetic algorithm), Female, Observational study, Colorectal Neoplasms, business, medicine.drug
Abstract

Aims: BEAWARE investigated the pattern of first-line bevacizumab early interruption in the Italian real-world setting of metastatic colorectal cancer. Methods: A total of 386 patients were followed for 15 months after first-line chemotherapy + bevacizumab start. The rate of bevacizumab interruption for progression or adverse drug reactions (ADRs) constituted the primary endpoint. Results: A total of 78.2% of patients interrupted bevacizumab: 56.6% for progression, 7.3% for ADRs, and 36.1% for other reasons. Median treatment duration was 6.7, 2.5, and 4.6 months, respectively. Median progression-free survival was 10.3 months; however, 35.8% of patients were not progressed and were thus censored at the data cutoff of 15 months, while 21.8% were still receiving bevacizumab. Patients discontinuing for progression/ADRs more frequently had metastases in >1 site ( p = .0001), and a shorter median progression-free survival (6.9 vs 13.9 months, p < .0001). Conclusions: In Italy, first-line bevacizumab is interrupted mainly for progression, only 7.3% due to adverse events, and about one third of cases for other reasons. In clinical practice, the attitude to treat until progression as per guidelines might be implemented. ClinicalTrials.gov Identifier: NCT01609075

Published
2019

18. Conservation status of the Italian flora under the 92/43/EEC ‘Habitats’ Directive

Author

Fenu, G, Siniscalco, C, Bacchetta, G, Cogoni, D, Silvia Pinna, M, Sarigu, M, Abeli, T, Barni, E, Bartolucci, F, Bouvet, D, Cogoni, A, Conti, F, Croce, A, Di Gristina, E, Domina, G, Ferretti, G, Gargano, D, Gennai, M, Montagnani, C, Oriolo, G, Orsenigo, S, Proietti, E, Puglisi, M, Rossi, G, Santangelo, A, Strazzaboschi, L, Turcato, C, Vena, M, Zappa, E, Giacanelli, V, Ercole, S, Giuseppe Fenu, Consolata Siniscalco, Gianluigi Bacchetta, Donatella Cogoni, Maria Silvia Pinna, Marco Sarigu, Thomas Abeli, Elena Barni, Fabrizio Bartolucci, Daniela Bouvet, Annalena Cogoni, Fabio Conti, Antonio Croce, Emilio Di Gristina, Gianniantonio Domina, Giulio Ferretti, Domenico Gargano, Matilde Gennai, Chiara Montagnani, Giuseppe Oriolo, Simone Orsenigo, Elisa Proietti, Marta Puglisi, Graziano Rossi, Annalisa Santangelo, Luca Strazzaboschi, Claudia Turcato, Maurizio Vena, Elena Zappa, Valeria Giacanelli, Stefania Ercole, Fenu, G, Siniscalco, C, Bacchetta, G, Cogoni, D, Silvia Pinna, M, Sarigu, M, Abeli, T, Barni, E, Bartolucci, F, Bouvet, D, Cogoni, A, Conti, F, Croce, A, Di Gristina, E, Domina, G, Ferretti, G, Gargano, D, Gennai, M, Montagnani, C, Oriolo, G, Orsenigo, S, Proietti, E, Puglisi, M, Rossi, G, Santangelo, A, Strazzaboschi, L, Turcato, C, Vena, M, Zappa, E, Giacanelli, V, Ercole, S, Giuseppe Fenu, Consolata Siniscalco, Gianluigi Bacchetta, Donatella Cogoni, Maria Silvia Pinna, Marco Sarigu, Thomas Abeli, Elena Barni, Fabrizio Bartolucci, Daniela Bouvet, Annalena Cogoni, Fabio Conti, Antonio Croce, Emilio Di Gristina, Gianniantonio Domina, Giulio Ferretti, Domenico Gargano, Matilde Gennai, Chiara Montagnani, Giuseppe Oriolo, Simone Orsenigo, Elisa Proietti, Marta Puglisi, Graziano Rossi, Annalisa Santangelo, Luca Strazzaboschi, Claudia Turcato, Maurizio Vena, Elena Zappa, Valeria Giacanelli, and Stefania Ercole

Abstract

The results of the 4th National Report for the Italian flora under the 92/43/EEC ‘Habitats’ Directive are presented. The outcomes showed a general negative conservation status for plant species, with the worst situation being in the Mediterranean bioregion. At the National level, significant monitoring and conservation activities are required.

Published
2021

22. Clinical and Immunological Outcome in High-risk Resected 1 Melanoma Patients Receiving Peptide-based Vaccination and 2 Interferon Alpha, with or without Dacarbazine Preconditioning: a 3 Phase II Study

Author

Urbani F., Ferraresi V, Capone I., Macchia I., Palermo B., Nuzzo C., Torsello A., Pezzotti P., Giannarelli D., Pozzi A.F., Santaquilani M., Roazzi P., Bastucci S., Catricalà C., La Malfa A., Vercillo G., Gualtieri N., Buccione C., Castiello L., Cognetti F., Nisticò P., Belardelli F., Moschella F., and Proietti E

Subjects
chemotherapy, combination therapy, drug repurposing, immunotherapy, interferon-?, melanoma
Abstract

Clinical studies based on novel rationales and mechanisms of action of chemotherapy agents and cytokines can contribute to the development of new concepts and strategies of antitumor combination therapies. In previous studies, we investigated the paradoxical immunostimulating effects of some chemotherapeutics and the immunoadjuvant activity of interferon alpha (IFN-?) in preclinical and clinical models, thus unraveling novel rationales and mechanisms of action of chemotherapy agents and cytokines for cancer immunotherapy. Here, we carried out a randomized, phase II clinical trial, in which we analyzed the relapse-free (RFS) and overall survival (OS) of 34 completely resected stage III-IV melanoma patients, treated with peptide-based vaccination (Melan-A/MART-1 and NY-ESO-1) in combination with IFN-?2b, with (arm 2) or without (arm 1) dacarbazine preconditioning. All patients were included in the intention-to-treat analysis. At a median follow-up of 4.5 years (interquartile range, 15.4-81.0 months), the rates of RFS were 52.9 and 35.3% in arms 1 and 2, respectively. The 4.5-year OS rates were 68.8% in arm 1 and 62.7% in arm 2. No significant differences were observed between the two arms for both RFS and OS. Interestingly, the RFS and OS curves remained stable starting from 18 and 42 months, respectively. Grade 3 adverse events occurred in 5.9% of patients, whereas grade 4 events were not observed. Both treatments induced a significant expansion of vaccine-specific CD8+ T cells, with no correlation with the clinical outcome. However, treatment-induced increase of polyfunctionality and of interleukin 2 production by Melan-A-specific CD8+ T cells and expansion/activation of natural killer cells correlated with RFS, being observed only in nonrelapsing patients. Despite the recent availability of different therapeutic options, low-cost, low-toxic therapies with long-lasting clinical effects are still needed in patients with high-risk resected stage III/IV melanoma. The combination of peptide vaccination with IFN-?2b showed a minimal toxicity profile and resulted in encouraging RFS and OS rates, justifying further evaluation in clinical trials, which may include the use of checkpoint inhibitors to further expand the antitumor immune response and the clinical outcome. Clinical Trial Registration: https://www.clinicaltrialsregister.eu/ctr-search/search, identifier: 2008-008211-26.

Published
2020
Full Text
View/download PDF

25. Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation

Author

Mondanelli, G., Coletti, A., Greco, F. A., Pallotta, M. T., Orabona, C., Iacono, A., Belladonna, M. L., Albini, E., Panfili, E., Fallarino, F., Gargaro, M., Manni, G., Matino, D., Carvalho, A., Cunha, C., Maciel, P., Filippo, M. D., Gaetani, L., Bianchi, R., Vacca, C., Iamandii, I. M., Proietti, E., Boscia, F., Annunziato, L., Peppelenbosch, M., Puccetti, P., Calabresi, Paolo, Macchiarulo, A., Santambrogio, L., Volpi, C., Grohmann, U., Calabresi P. (ORCID:0000-0003-0326-5509), Mondanelli, G., Coletti, A., Greco, F. A., Pallotta, M. T., Orabona, C., Iacono, A., Belladonna, M. L., Albini, E., Panfili, E., Fallarino, F., Gargaro, M., Manni, G., Matino, D., Carvalho, A., Cunha, C., Maciel, P., Filippo, M. D., Gaetani, L., Bianchi, R., Vacca, C., Iamandii, I. M., Proietti, E., Boscia, F., Annunziato, L., Peppelenbosch, M., Puccetti, P., Calabresi, Paolo, Macchiarulo, A., Santambrogio, L., Volpi, C., Grohmann, U., and Calabresi P. (ORCID:0000-0003-0326-5509)

Abstract

L-tryptophan (Trp), an essential amino acid for mammals, is the precursor of a wide array of immunomodulatory metabolites produced by the kynurenine and serotonin pathways. The kynurenine pathway is a paramount source of several immunoregulatory metabolites, including L-kynurenine (Kyn), the main product of indoleamine 2,3-dioxygenase 1 (IDO1) that catalyzes the rate-limiting step of the pathway. In the serotonin pathway, the metabolite N-acetylserotonin (NAS) has been shown to possess antioxidant, antiinflammatory, and neuroprotective properties in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). However, little is known about the exact mode of action of the serotonin metabolite and the possible interplay between the 2 Trp metabolic pathways. Prompted by the discovery that NAS neuroprotective effects in EAE are abrogated in mice lacking IDO1 expression, we investigated the NAS mode of action in neuroinflammation. We found that NAS directly binds IDO1 and acts as a positive allosteric modulator (PAM) of the IDO1 enzyme in vitro and in vivo. As a result, increased Kyn will activate the ligand-activated transcription factor aryl hydrocarbon receptor and, consequently, antiinflammatory and immunoregulatory effects. Because NAS also increased IDO1 activity in peripheral blood mononuclear cells of a significant proportion of MS patients, our data may set the basis for the development of IDO1 PAMs as first-in-class drugs in autoimmune/neuroinflammatory diseases.

Published
2020

26. Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Author

Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G, Aimone P, Cignetti A, Casorati G, Castelli C, Del Vecchio M, Di Giacomo AM, Di Nicola M, Fais F, Ferrini S, Fontana R, Iovino F, Lander T, Maccalli C, Manfredi A, Neyroz P, Nisticò P, Pellegatta S, Proietti E, Rivoltini L, Rosato A, Santoni A, Sigalotti L., LOLLINI, PIER LUIGI, Maio M, Nicolay HJ, Ascierto PA, Belardelli F, Camerini R, Colombo MP, Queirolo P, Ridolfi R, Russo V, Fonsatti E, Parmiani G, Aimone P, Cignetti A, Casorati G, Castelli C, Del Vecchio M, Di Giacomo AM, Di Nicola M, Fais F, Ferrini S, Fontana R, Iovino F, Lander T, Lollini PL, Maccalli C, Manfredi A, Neyroz P, Nisticò P, Pellegatta S, Proietti E, Rivoltini L, Rosato A, Santoni A, and Sigalotti L

Subjects
Cancer Research, Oncology, Immunology, Immunology and Allergy
Published
2009

30. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey

Author

Natoli, C., Brocco, D., Sperduti, I., Nuzzo, A., Tinari, N., De Tursi, M., Grassadonia, A., Mazzilli, L., Iacobelli, S., Gamucci, T., Vici, P., Study, Group, Adamo, V., Airoldi, M., Amoroso, D., Angelini, F., Angiolini, C., Angiolucci, G., Ardizzoia, A., Baldini, E., Ballardini, P., Barni, S., Barone, C., Battelli, N., Bernardi, D., Bianchetti, S., Bianco, N., Biglia, Nicoletta, Bilancia, D., Biti, G., Boni, C., Bordonaro, R., Botta, M., Bretti, S., Brunello, A., Brunetti, C., Bruno, D., Bucci, E., Buzzoni, R., Cagossi, K., Cappelletti, C., Cappuzzo, F., Cardillo, F., Carroccio, R., Cascinu, S., Cavanna, L., Cianchetti, E., Clerico, M., Contu, A., Corsi, D., Cortesi, L., Cretella, E., Crispino, S., Di Lieto, M., Di Lullo, L., Durini, E., Fabi, A., Failla, G., Fattorusso, S., Ferraù, F., Ferro, A., Ficorella, C., Fogazzi, G., Foglietta, J., Francini, G., Fusco, O., Gennari, A., Ghiani, M., Gianni, L., Giordano, M., Giotta, F., Giuliani, R., Gori, S., Graiff, C., Guarneri, V., Guarneri, D., Guglielmi, F., Landriscina, M., Laudadio, L., Lombardo, M., Longo, F., Macellari, G., Madeddu, C., Magnanini, S., Maiorino, L., Mangiameli, A., Marini, G., Massidda, B., Mattioli, R., Michelotti, A., Molino, A., Montesarchio, V., Morale, A., Murgo, R., Naso, G., Natale, D., Orditura, M., Orrù, S., Pace, R., Palazzo, A., Palma, F., Pancotti, A., Pandoli, G., Papaldo, P., Parisi, A. M., Passalacqua, R., Pellegrino, A., Perrucci, B., Proietti, E., Recchia, F., Riccardi, F., Rispoli, A. I., Rocca, A., Romaniello, I., Rossetti, R., Rossi, D., Rosti, G., Ruggeri, E. M., Russo, A., Savarino, A., Savastano, C., Scognamiglio, G., Scognamiglio, M., Seminara, P., Serrachini, S., Sidoti, V., Silva, R. R., Surace, G., Tomao, S., Tonini, G., Trenta, P., Turazza, M., Valenza, R., Veltri, E., Zampa, G., Zaniboni, A., Zanirato, S., C, Natoli, D, Brocco, I, Sperduti, A, Nuzzo, N, Tinari, M, De Tursi, A, Grassadonia, L, Mazzilli, S, Iacobelli, T, Gamucci, P, Vici, Study Group, 'FOLLOW-UP', and Orditura, Michele

Subjects
Oncology, breast cancer, Follow-up, survey, Medical Oncology, law.invention, Randomized controlled trial, law, Aged, Breast Neoplasms, Female, Follow-Up Studies, Health Care Surveys, Humans, Italy, Middle Aged, Secondary Prevention, Guideline Adherence, Breast Tumors, Medicine and Health Sciences, Web based survey, Multidisciplinary, Pharmaceutics, Surgical Oncology, Cancer Therapy, Medicine, medicine.symptom, Disease staging, Research Article, medicine.medical_specialty, Adjuvant Cancer Chemotherapy, Science, MEDLINE, Asymptomatic, Breast cancer, Drug Therapy, Internal medicine, medicine, Cancer Detection and Diagnosis, Chemotherapy, Modalities, business.industry, Cancers and Neoplasms, medicine.disease, Blood chemistry, Women's Health, Clinical Medicine, business
Abstract

PurposeBreast cancer follow-up procedures after primary treatment are still a controversial issue. Aim of this study was to investigate, through a web-based survey, surveillance methodologies selected by Italian oncologists in everyday clinical practice.MethodsReferents of Italian medical oncology units were invited to participate to the study via e-mail through the SurveyMonkey website. Participants were asked how, in their institution, exams of disease staging and follow-up are planned in asymptomatic women and if surveillance continues beyond the 5th year.ResultsBetween February and May 2013, 125 out of 233 (53.6%) invited referents of Italian medical oncology units agreed to participate in the survey. Ninety-seven (77.6%) referents state that modalities of breast cancer follow-up are planned according to the risk of disease progression at diagnosis and only 12 (9.6%) oncology units apply the minimal follow-up procedures according to international guidelines. Minimal follow-up is never applied in high risk asymptomatic women. Ninety-eight (78.4%) oncology units continue follow-up in all patients beyond 5 years.ConclusionsOur survey shows that 90.4% of participating Italian oncology units declare they do not apply the minimal breast cancer follow-up procedures after primary treatment in asymptomatic women, as suggested by national and international guidelines. Interestingly, about 80.0% of interviewed referents performs the so called "tailored follow-up", high intensity for high risk, low intensity for low risk patients. There is an urgent need of randomized clinical trials able to determine the effectiveness of risk-based follow-up modalities, their ideal frequency and persistence in time.

Published
2014

31. Breast cancer 'tailored follow-up' in Italian oncology units: a web-based survey

Author

Natoli, C, Adamo, V, Airoldi, M, Amoroso, D, Angelini, F, Angiolini, C, Angiolucci, G, Ardizzoia, A, Baldini, E, Ballardini, P, Barni, S, Barone, C, Battelli, N, Bernardi, D, Bianchetti, S, Bianco, N, Biglia, N, Bilancia, D, Biti, G, Boni, C, Bordonaro, R, Botta, M, Bretti, S, Brunello, A, Brunetti, C, Bruno, D, Bucci, E, Buzzoni, R, Cagossi, K, Cappelletti, C, Cappuzzo, F, Cardillo, F, Carroccio, R, Cascinu, S, Cavanna, L, Cianchetti, E, Clerico, M, Contu, A, Corsi, D, Cortesi, L, Cretella, E, Crispino, S, Di Lieto, M, Di Lullo, L, Durini, E, Fabi, A, Failla, G, Fattorusso, S, Ferraù, F, Ferro, A, Ficorella, C, Fogazzi, G, Foglietta, J, Francini, G, Fusco, O, Gennari, A, Ghiani, M, Gianni, L, Giordano, M, Giotta, F, Giuliani, R, Gori, S, Graiff, C, Guarneri, V, Guarneri, D, Guglielmi, F, Landriscina, M, Laudadio, L, Lombardo, M, Longo, F, Macellari, G, Madeddu, C, Magnanini, S, Maiorino, L, Mangiameli, A, Marini, G, Massidda, B, Mattioli, R, Michelotti, A, Molino, A, Montesarchio, V, Morale, A, Murgo, R, Naso, Giuseppe, Natale, D, Orditura, M, Orrù, S, Pace, R, Palazzo, Antonella, Palma, F, Pancotti, A, Pandoli, G, Papaldo, P, Parisi, Am, Passalacqua, R, Pellegrino, A, Perrucci, B, Proietti, E, Recchia, F, Riccardi, F, Rispoli, Ai, Rocca, A, Romaniello, I, Rossetti, R, Rossi, D, Rosti, G, Ruggeri, Em, Russo, A, Savarino, A, Savastano, C, Scognamiglio, G, Scognamiglio, M, Seminara, Patrizia, Serrachini, S, Sidoti, V, Silva, Rr, Surace, G, Tomao, Silverio, Tonini, G, Trenta, P, Turazza, M, Valenza, R, Veltri, E, Zampa, G, Zaniboni, A, and Zanirato, S.

Published
2014

35. Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: A multicentre nationwide study 2000-12

Author

Piccoli, G, Postorino, V, Cabiddu, G, Ghiotto, S, Guzzo, G, Roggero, S, Manca, E, Puddu, R, Meloni, F, Attini, R, Moi, P, Maxia, S, Piga, A, Mazzone, L, Pani, A, Postorino, M, Castellino, S, Gernone, G, Guida, B, Calabria, S, Galliani, M, Manisco, G, Di Tullio, M, Vernaglione, L, Chiappini, M, Proietti, E, Saffiotti, S, Gangeni, C, Brunati, C, Montoli, A, Esposito, C, Montagna, G, Tata, S, Romano, P, Amatruda, O, Cervini, P, Casiraghi, E, Fabbrini, P, Pieruzzi, F, Di Benedetto, A, Alfisi, G, Heidempergher, M, Buskermolen, M, Leveque, A, Autuly, V, Giofrè, F, Alati, G, Lombardi, L, Riccio, M, Riccio, I, Stingone, A, D'Angelo, B, Lucchi, L, Stipo, L, Loi, V, Piccoli, G, Postorino, V, Cabiddu, G, Ghiotto, S, Guzzo, G, Roggero, S, Manca, E, Puddu, R, Meloni, F, Attini, R, Moi, P, Maxia, S, Piga, A, Mazzone, L, Pani, A, Postorino, M, Castellino, S, Gernone, G, Guida, B, Calabria, S, Galliani, M, Manisco, G, Di Tullio, M, Vernaglione, L, Chiappini, M, Proietti, E, Saffiotti, S, Gangeni, C, Brunati, C, Montoli, A, Esposito, C, Montagna, G, Tata, S, Romano, P, Amatruda, O, Cervini, P, Casiraghi, E, Fabbrini, P, Pieruzzi, F, Di Benedetto, A, Alfisi, G, Heidempergher, M, Buskermolen, M, Leveque, A, Autuly, V, Giofrè, F, Alati, G, Lombardi, L, Riccio, M, Riccio, I, Stingone, A, D'Angelo, B, Lucchi, L, Stipo, L, and Loi, V

Abstract

Background Pregnancy on dialysis is increasingly being reported. This study evaluates the behavioural profile of the children of mothers on dialysis and the parental stress their mothers undergo when compared with a group of mothers affected by a different chronic disease (microcythaemia) and a group of healthy control mothers. Methods Between 2000 and 2012, 23 on-dialysis mothers gave birth to 24 live-born children in Italy (23 pregnancies, 1 twin pregnancy, one of the twins deceased soon after delivery); of these, 16 mothers and 1 father (whose wife died before the inquiry) were included in the study (1 mother had died and the father was unavailable; 2 were not asked to participate because their children had died and 3 were unavailable; children: median age: 8.5, min-max: 2-13 years). Twenty-three mothers affected by transfusion-dependent microcythaemia or drepanocitosis (31 pregnancies, 32 children) and 35 healthy mothers (35 pregnancies, 35 children; median age of the children: 7, min-max: 1-13 years) were recruited as controls. All filled in the validated questionnaires: 'Child Behaviour Checklist' (CBCL) and the 'Parental Stress Index-Short Form' (PSI-SF). Results The results of the CBCL questionnaire were similar for mothers on dialysis and healthy controls except for pervasive developmental problems, which were significantly higher in the dialysis group, while microcythaemia mothers reported higher emotional and behavioural problems in their children in 8 CBCL sub-scales. Two/16 children in the dialysis and 3/32 in the microcythaemia group had pathological profiles, as assessed by T-scores (p: ns). PSI-SF indicated a normal degree of parental stress in microcythaemia subjects and healthy controls, while mothers on dialysis declared significantly lower stress, suggesting a defensive response in order to minimize problems, stress or negativity in their relationship with their child. Conclusions According to the present analysis, the emotional and behavioural o

Published
2015

37. Wafer-level micropackaging in thin film technology for RF MEMS applications.

Author

Persano, A., Siciliano, P., Quaranta, F., Taurino, A., Lucibello, A., Marcelli, Romolo, Capoccia, G., Proietti, E., Bagolini, A., and Iannacci, J.

Subjects
MICROELECTROMECHANICAL systems, SEMICONDUCTOR wafers, THIN films, COPLANAR waveguides, SILICON nitride
Abstract

In this work, a thin-film packaging was developed to be used for radio-frequency microelectromechanical system configurations. The fabricated packages are suspended membranes in the multilayer SiN/aSi/SiN on conductive coplanar waveguides (CPWs) of different length. Several geometric parameters of the membranes, which are the length, the curvature radius at the vertices of the rectangular base, the density and the diameter of holes on the capping surface, were also varied. The mechanical properties of the suspended membranes were investigated by mechanical simulations and surface profilometry measurements as a function of the geometric parameters. RF characterization was performed to evaluate the impact of the package on the CPW performance. Finally, network analysis was carried out, allowing to clarify the origin of the RF losses measured for the fabricated microdevices. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

38. Consensus guidelines for the detection of immunogenic cell death

Author

Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., Bracci, L., Breckpot, K., Brough, D., Buqué, A., Castro, Mg, Cirone, M., Colombo, Mi, Cremer, I., Demaria, S., Dini, L., Eliopoulos, A., Faggioni, A., Formenti, Sc, Fu??íková, J., Gabriele, L., Gaipl, Us, Galon, J., Garg, A., Ghiringhelli, F., Giese, Na, Guo, Zs, Hemminki, A., Herrmann, M., Hodge, Jw, Holdenrieder, S., Honeychurch, J., Hm, Hu, Huang, X., Illidge, Tm, Kono, K., Korbelik, M., Krysko, Dv, Loi, S., Lowenstein, Pr, Lugli, E., Ma, Y., Madeo, F., Manfredi, Aa, Martins, I., Matzinger, P., Mavilio, D., Menger, L., Merendino, N., Michaud, M., Mignot, G., Mossman, Kl, Multhoff, G., Oehler, R., Palombo, F., Panaretakis, T., Pol, J., Proietti, E., Ricci, Je, Riganti, Chiara, Rovere Querini, P., Rubartelli, A., Sistigu, A., Smyth, Mj, Sonnemann, J., Spisek, R., Stagg, J., Sukkurwala, Aq, Tartour, E., Thorburn, A., Thorne, Sh, Vandenabeele, P., Velotti, F., Workenhe, Sr, Yang, H., Zong, Wx, Zitvogel, L., Kroemer, G., Galluzzi, L., Medicine and Pharmacy academic/administration, Basic (bio-) Medical Sciences, Laboratory of Molecullar and Cellular Therapy, Chemistry, Kepp, Oliver, Senovilla, Laura, Vitale, Ilio, Vacchelli, Erika, Adjemian, Sandy, Agostinis, Patrizia, Apetoh, Lionel, Aranda, Fernando, Barnaba, Vincenzo, Bloy, Norma, Bracci, Laura, Breckpot, Karine, Brough, David, Buqué, Aitziber, Castro, Maria G, Cirone, Mara, Colombo, Maria I, Cremer, Isabelle, Demaria, Sandra, Dini, Luciana, Eliopoulos, Aristides G, Faggioni, Alberto, Formenti, Silvia C, Fučíková, Jitka, Gabriele, Lucia, Gaipl, Udo S, Galon, Jérôme, Garg, Abhishek, Ghiringhelli, Françoi, Giese, Nathalia A, Guo, Zong Sheng, Hemminki, Akseli, Herrmann, Martin, Hodge, James W, Holdenrieder, Stefan, Honeychurch, Jamie, Hu, Hong Min, Huang, Xing, Illidge, Tim M, Kono, Koji, Korbelik, Mladen, Krysko, Dmitri V, Loi, Sherene, Lowenstein, Pedro R, Lugli, Enrico, Ma, Yuting, Madeo, Frank, Manfredi, Angelo A, Martins, Isabelle, Mavilio, Domenico, Menger, Laurie, Merendino, Nicolò, Michaud, Michael, Mignot, Gregoire, Mossman, Karen L, Multhoff, Gabriele, Oehler, Rudolf, Palombo, Fabio, Panaretakis, Theochari, Pol, Jonathan, Proietti, Enrico, Ricci, Jean Ehrland, Riganti, Chiara, Rovere Querini, Patrizia, Rubartelli, Anna, Sistigu, Antonella, Smyth, Mark J, Sonnemann, Juergen, Spisek, Radek, Stagg, John, Sukkurwala, Abdul Qader, Tartour, Eric, Thorburn, Andrew, Thorne, Stephen H, Vandenabeele, Peter, Velotti, Francesca, Workenhe, Samuel T, Yang, Haining, Zong, Wei Xing, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo, Kepp, O, Senovilla, L, Vitale, I, Vacchelli, E, Adjemian, S, Agostinis, P, Apetoh, L, Aranda, F, Barnaba, V, Bloy, N, Bracci, L, Breckpot, K, Brough, D, Buque, A, Castro, Mg, Cirone, M, Colombo, Mi, Cremer, I, Demaria, S, Dini, L, Eliopoulos, Ag, Faggioni, A, Formenti, Sc, Fucikova, J, Gabriele, L, Gaipl, U, Galon, J, Garg, A, Ghiringhelli, F, Giese, Na, Guo, Z, Hemminki, A, Herrmann, M, Hodge, Jw, Holdenrieder, S, Honeychurch, J, Hu, Hm, Huang, X, Illidge, Tm, Kono, K, Korbelik, M, Krysko, Dv, Loi, S, Lowenstein, Pr, Lugli, E, Ma, Yt, Madeo, F, Manfredi, ANGELO ANDREA M. A., Martins, I, Mavilio, D, Menger, L, Merendino, N, Michaud, M, Mignot, G, Mossman, Kl, Multhoff, G, Oehler, R, Palombo, F, Panaretakis, T, Pol, J, Proietti, E, Ricci, Je, Riganti, C, ROVERE QUERINI, Patrizia, Rubartelli, A, Sistigu, A, Smyth, Mj, Sonnemann, J, Spisek, R, Stagg, J, Sukkurwala, Aq, Tartour, E, Thorburn, A, Thorne, Sh, Vandenabeele, P, Velotti, F, Workenhe, St, Yang, Hn, Zong, Wx, Zitvogel, L, Kroemer, G, and Galluzzi, L.

Subjects
HSV-1, herpes simplex virus type I, Δψm, mitochondrial transmembrane potential, medicine.medical_treatment, DAMP, damage-associated molecular pattern, detection, FLT3LG, fms-related tyrosine kinase 3 ligand, Review, member 3, calreticulin, Eukaryotic translation initiation factor 2A, RFP, red fluorescent protein, 0302 clinical medicine, MOMP, mitochondrial outer membrane permeabilization, Immunology and Allergy, GFP, green fluorescent protein, HMGB1, 0303 health sciences, education.field_of_study, Toll-like receptor, BAK1, BCL2-antagonist/killer 1, H2B, histone 2B, endoplasmic reticulum stre, 3. Good health, BAX, BCL2-associated X protein, XBP1, X-box binding protein 1, cell death, Oncology, PDIA3, protein disulfide isomerase family A, 030220 oncology & carcinogenesis, endoplasmic reticulum stress, Immunogenic cell death, HSP, heat shock protein, immunotherapy, TLR, Toll-like receptor, autophagy, ATF6, activating transcription factor 6, Immunology, ICD, immunogenic cell death, EIF2A, eukaryotic translation initiation factor 2A, Guidelines, Biology, BCL2, B-cell CLL/lymphoma 2 protein, ER, endoplasmic reticulum, PI, propidium iodide, ATP release, 03 medical and health sciences, Immune system, immunogenic, medicine, IFN, interferon, Antigen-presenting cell, education, 030304 developmental biology, CALR, calreticulin, Damage-associated molecular pattern, Immunotherapy, CTL, cytotoxic T lymphocyte, HMGB1, high mobility group box 1, IL, interleukin, G3BP1, GTPase activating protein (SH3 domain) binding protein 1, APC, antigen-presenting cell, Cancer cell, DiOC6(3), 3,3′-dihexyloxacarbocyanine iodide, DAPI, 4′,6-diamidino-2-phenylindole
Abstract

Apoptotic cells have long been considered as intrinsically tolerogenic or unable to elicit immune responses specific for dead cell-associated antigens. However, multiple stimuli can trigger a functionally peculiar type of apoptotic demise that does not go unnoticed by the adaptive arm of the immune system, which we named "immunogenic cell death" (ICD). ICD is preceded or accompanied by the emission of a series of immunostimulatory damage-associated molecular patterns (DAMPs) in a precise spatiotemporal configuration. Several anticancer agents that have been successfully employed in the clinic for decades, including various chemotherapeutics and radiotherapy, can elicit ICD. Moreover, defects in the components that underlie the capacity of the immune system to perceive cell death as immunogenic negatively influence disease outcome among cancer patients treated with ICD inducers. Thus, ICD has profound clinical and therapeutic implications. Unfortunately, the gold-standard approach to detect ICD relies on vaccination experiments involving immunocompetent murine models and syngeneic cancer cells, an approach that is incompatible with large screening campaigns. Here, we outline strategies conceived to detect surrogate markers of ICD in vitro and to screen large chemical libraries for putative ICD inducers, based on a high-content, high-throughput platform that we recently developed. Such a platform allows for the detection of multiple DAMPs, like cell surface-exposed calreticulin, extracellular ATP and high mobility group box 1 (HMGB1), and/or the processes that underlie their emission, such as endoplasmic reticulum stress, autophagy and necrotic plasma membrane permeabilization. We surmise that this technology will facilitate the development of next-generation anticancer regimens, which kill malignant cells and simultaneously convert them into a cancer-specific therapeutic vaccine. peerreview_statement: The publishing and review policy for this title is described in its Aims & Scope. aims_and_scope_url: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=koni20 ispartof: OncoImmunology vol:3 issue:9 pages:12472-124508 ispartof: location:United States status: published

Published
2014

40. Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study

Author

Franceschi, E., primary, Finocchiaro, G., additional, Zagonel, V., additional, Reni, M., additional, Fabi, A., additional, Caserta, C., additional, Clavarezza, M., additional, Maiello, E., additional, Carteni, G., additional, Rosti, G., additional, Agati, R., additional, Tosoni, A., additional, Proietti, E., additional, Paccapelo, A., additional, and Brandes, A.A., additional

Published
2015
Full Text
View/download PDF

47. Reliable RF Microsystem Technologies for Space Applications

Author

Marcelli, R., Proietti, E., Lucibello, A., De Angelis, E., Bartolucci, G., Quaranta, F., Martucci, C., Persano, A., Mannocchi, G., Di Nardo, S., Pochesci, D., Margesin, B., Giacomozzi, F., Casini, F., and Farinelli, Paola

Subjects
Space Applications, RF MEMS, Reliability
Abstract

RF Micro-Electro Mechanical Systems (MEMS) have been developed during the last decade with several applications for commercial as well as space and military sub-systems [1-6]. Technological processes encompassing the utilization of typical microelectronic substrates like alumina, GaAs and Silicon have been considered for the realization of micro-switches by surface micromachining. True time delay lines (TTDL), single port multiple throw (SPMT), matrices and phase shifters take benefit from the low insertion loss, all passive and distortion-free environment offered by RF MEMS. Antenna re-configuration through digital phase shifters based on RF MEMS switches are currently studied.

Published
2010

48. PREGNANCY AND PROGRESSION OF IGA NEPHROPATHY: RESULTS OF AN ITALIAN MULTICENTER STUDY

Author

Limardo, M, Imbasciati, E, Ravani, P, Surian, M, Torres, D, Gregorini, G, Magistroni, R, Casellato, D, Gammaro, L, Pozzi, C, Gammaro L, Rene e. Gravidanza Collaborative Group of the Italian Society of N. e. p. h. r. o. l. o. g. y., Beati, S, Ambroso, G, Maggio, M, Del Giudice, A, De Cristofaro, V, Gallo, E, Gernone, G, Marega, A, Rustichelli, R, Cabiddu, G, Rollino, C, Fanciulli, E, Feriozzi, S, Pecchini, P, Bizzarri, D, D'Amico, M, Proietti, E, Baratelli, L, Battista Reinero, G, Garibotto, Giacomo, Rocchietti, M, Allegri, L, Dugo, M, Cirami, L, Esposito, C, Amico, L, Mariani, P, Baroli, A, Giannattasio, M, Stratta, P, Montanaro, D, Gesualdo, L, Daidone, G, Manfellotto, D, and Castellino, S.

Published
2010

49. Reliability of RF MEMS switches due to charging effects and their circuital modelling

Author

Marcelli, R. Bartolucci, G. Papaioannu, G. De Angelis, G. Lucibello, A. Proietti, E. Margesin, B. Giacomozzi, F. Deborgies, F.

Subjects
GeneralLiterature_INTRODUCTORYANDSURVEY, Hardware_GENERAL
Abstract

The reliability of RF MEMS switches is typically reduced by charging effects occurring in the dielectrics. The aim of this paper is to discuss these effects, and to propose analytical and equivalent circuit models which account for most of the physical contributions present in the structure. © 2009 Springer-Verlag.

Published
2010

50. RF MEMS ohmic switches for matrix configurations

Author

De Angelis, G., Lucibello, A., Casini, F., Farinelli, Paola, Mannocchi, G., Di Nardo, S., Margesin, B., Giacomozzi, F., Vendier, O., Vietzorreck, L., Proietti, E., and Marcelli, R.

Subjects
Matrix, CPW, RF MEMS, SPST
Abstract

Two different topologies of RF MEMS series ohmic switches (cantilever and clamped - clamped beams) in Coplanar Waveguide (CPW) configuration have been characterized by means of DC, environmental and RF measurements. The devices have been manufactured on High Resistivity (HR) Silicon substrates, as building blocks to be implemented in different Single-Pole 4-Throw (SP4T), Double-Pole Double-Throw (DPDT) configurations and then integrated in LTCC technology for the realization of Large Order Clos 3D networks.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results